| 0.5746 -0.255 (-30.77%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.84 | 1-year : | 0.93 |
| Resists | First : | 0.71 | Second : | 0.8 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.58 | Second : | 0.49 |
| MAs | MA(5) : | 0.6 |
MA(20) : | 0.67 |
| MA(100) : | 0.65  |
MA(250) : | 1.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0.1 |
D(3) : | 1.7 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 4.76 | Low : | 0.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KA ] has closed above bottom band by 9.7%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.61 - 0.62 | 0.62 - 0.62 |
| Low: | 0.58 - 0.59 | 0.59 - 0.59 |
| Close: | 0.58 - 0.59 | 0.59 - 0.6 |
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Mon, 23 Jun 2025
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - PR Newswire
Thu, 24 Apr 2025
KA Stock Price, News & Analysis - Stock Titan
Thu, 19 Sep 2024
Kineta shares to be delisted from Nasdaq - Investing.com
Tue, 30 Apr 2024
BioWorld Cancer Index ends Q1 up on pipeline progress, despite restructurings - BioWorld MedTech
Thu, 29 Feb 2024
Kineta CEO laid off as cutbacks leave biotech with 4 employees - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 34.8 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 29 (K) |
| Shares Short P.Month | 91 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -114.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.37 |
| PEG Ratio | 0 |
| Price to Book value | -0.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2000-01-10 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|